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Type I and type III collagen metabolites in adult osteosarcoma patients
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Summary Three biochemical markers of collagen metabolism were measured in 39 osteosarcoma patients.
The pretreatment values did not predict outcome, and the markers showed no consistent change upon
development of metastases. Both the age of the patients and the multimodality therapy affected the collagen
metabolites. These findings emphasise the need for cautious interpretation of tumour-associated markers.
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We have previously shown that the amino-terminal propep-
tide of type III procollagen (PIIINP) is a prognostic factor in
soft tissue sarcomas (Wiklund et al., 1992). PIIINP was
elevated particularly in the case of bone involvement of the
tumour. Recently PIIINP has been shown to be both a
prognostic factor and to reflect the clinical behaviour of
multiple myeloma (Taube et al., 1992). In this disease also
the cross-linked carboxy-terminal telopeptide of type I coll-
agen (ICTP) is a prognostic factor, a measure of the extent of
bone lesions and a sensitive marker of regression of the
disease (Elomaa et al., 1992; Abildgaard et al., 1994). Both
ICTP and the carboxy-terminal propeptide of type I procoll-
agen, PICP, are elevated in prostate cancer with bone metas-
tases (Kylmala et al., 1993, 1995). Type I collagen is the
major protein of mineralised bone, accounting for about
90% of its organic matrix, whereas type III collagen is an
important matrix constituent of soft tissues, including the
bone marrow and periosteum (Risteli and Risteli, 1989).
Thus, it seemed relevant to study these three metabolites,
which measure synthesis (PIIINP, PICP) as well as degrada-
tion (ICTP) of collagen types I and III in osteosarcoma, a
malignant primary bone tumour.
Materials and methods
Patients
Between 1986 and 1993 25 new patients with osteosarcoma
attended Helsinki University Central Hospital. Four patients
were operated before referral (incorrect preoperative diag-
nosis). Three patients had metastatic disease at time of diag-
nosis. Thus 18 patients had osteosarcoma, stage MO and
received preoperative chemotherapy. The mean age of these
patients was 22 years (range 15-55, nine below 20 years of
age); ten of them were men. Ten of the tumours were in the
thigh, four in the lower leg, two in the pelvis and two in the
upper extremity. The preoperative chemotherapy consisted of
high-dose methotrexate, and, since 1989, also of doxorubicin
and cisplatin (five patients).
One patient did not receive methotrexate as a result of
erroneous preoperative diagnosis of Ewing's sarcoma. Fifteen
patients were amputated, in three, limb-sparring surgery was
performed. The histological response to chemotherapy was
poor (grade 1-2) in 14 patients, and good (grade 4) in four
patients. Post-operatively all patients received combination
chemotherapy. Ten patients have had metastases during the
follow-up. The median follow-up of the patients alive is 76
months (37-102 months). Eight patients have died.
In addition to those ten patients who had received
preoperative chemotherapy and subsequently had metastases,
all four patients who did not receive preoperative chemo-
therapy had metastases during the follow-up. Three patients
had metastases at time of diagnosis. Thus 17 patients with
metastatic disease could be studied.
Finally, 14 patients who had been treated before 1986 and
were in continuous remission were included during the
disease-free follow-up.
Serum samples were obtained before the start of the
preoperative chemotherapy, after surgery and during the last
cycle of post-operative chemotherapy, as well as at each
follow-up visit, and at the time of the detection of metas-
tases. Since 1989 serum has also been collected regularly
during the pre- and post-operative chemotherapy (11
patients). The blood samples were obtained in the morning.
The sera were stored at -20'C until analysed.
Assays
The assays for PIIINP, PICP and ICTP have previously been
reported in detail (Melkko et al., 1990; Risteli et al., 1988,
1993). The reference intervals among healthy Finnish blood
donors over 20 years of age are as follows: PIIINP
1.7-4.3figl-' (Risteli et al., 1988), PICP 50-170igl-' for
women and 40-200 fig 1- for men (Melkko et al., 1990) and
ICTP 1.7-4.6 fig 1' (Risteli et al., 1993). For patients less
than 20 years old the upper limit of the reference range is
higher, particularly for ICTP in young men (about 11 jig 1-l
in men 16-18 years old, and about 9jsgl- in men 18-20
years old) (P Trivedi and J Risteli, unpublished data). The
intra- and interassay coefficient of variation for the assays are
around 5%.
Statistical analysis
The changes in collagen metabolites within the patients were
studied with the Wilcoxon signed-rank test. Correlations
between the different metabolites, and between the meta-
bolites and age were assessed by the Spearman's rank-order
correlation coefficient (rj). The effect on different variables on
survival was studied with the method of proportional
hazards. In these analyses the log transformed values of the
metabolites were used as continuous variables.
Results
Pretreatment values
The pretreatment concentrations of PIIINP, PICP and ICTP
are shown in Table I. There is no difference between the
concentrations obtained for those patients who later rem-
ained in continuous remission and those with a later relapse
of the disease. For alkaline phosphatase (AP) and lactate
Correspondence: T Wiklund,
Department of Radiotherapy and Oncology, Helsinki University
Central Hospital, Haartmaninkatu 4, FIN - 00290 Helsinki, Finland.
Received 7 June 1995; revised 31 July 1995; accepted 2 August 1995Collagen metabolites in osteosarcoma
T Wiklund et al
107
Table I Themean baseline (= before thestart ofthepreoperative chemotherapy)values, rangeandproportion
above the reference range of PIIINP, PICP and ICTP in all MO patients, and separately for patients
subsequently in continuous remission or who have had a relapse
PICP (pig 1-1)
PIIINP (pg 1') 50-170 (women) ICTP (pg 1')
Reference range 1.7-4.3 40-200 (men) 1.7-4.6
All patients (n = 18)
Mean 5.3 134 9.4
Range 3-11.8 73-267 2.5-18.3
Proportion above reference range 61% 17% 78%
Continuous remission (n = 8)
Mean 4.6 134 8.5
Range 3.2-6 73-267 3.1 -17
Proportion above reference range 63% 25% 63%
Relapse (n = 10)
Mean 5.8 133 10.2
Range 3- 11.8 75- 195 2.5-18.3
Proportion above reference range 60% 10% 90%
PIIINP, the amino-terminal propeptide of type III procollagen; PICP, the carboxy-terminal propeptide of
type I procollagen; ICTP, the mature, pyridoline or pyrrole cross-linked carboxy-terminal telopeptide oftype I
collagen.
dehydrogenase (LD) the mean pretreatment activities were
585 U 1' (range 115-2178) and 405 U 1` (261-721) respec-
tively.
There was a statistically significant positive correlation
between the baseline PIIINP and PICP (r, = 0.54, P = 0.02),
between PIIINP and ICTP (rs = 0.49, P= 0.04), but not
between PICP and ICTP or between the collagen metabolites
and AP or LD. In addition there was a statistically
significant negative correlation between age and ICTP
(rs = -0.68, P = 0.005), but not between age and other col-
lagen metabolites, or AP or LD and age.
None of the collagen metabolites were prognostic factors for
survival at baseline. However, AP and LD were significant
prognostic factors for both overall and metastases-free sur-
vival (P = 0.04 and 0.03 respectively).
Metastatic disease
In metastatic disease the mean PIIINP was 4.4 pg 1'
(2.7-6.9 plg I-', 60% above reference range), PICP 107 pLg l-'
(36-200p,g1-', 20%), and ICTP 7.9pg1-' (3.2-22.3pLgl1',
67%). In patients with both baseline values and values at
time of metastases available these did not differ significantly.
There was no rising level of the metabolites preceding the
detection of metastases (Figure la-c).
Effect ofthe treatment
All the metabolites decreased from baseline during the
preoperative chemotherapy. This decrease was statistically
significant for PIIINP and PICP (P = 0.009 and 0.004 res-
pectively). The mean change was - 1.2 pg 1' and -44.5
pg 1 ', respectively, and samples were obtained before
surgery a mean of 37 days after the start of the
chemotherapy (range 14-77 days). Post-operatively ICTP
was significantly above the baseline (P=0.04), the mean
change was 2.3 Lg 1-', samples taken a mean of 16 days
post-operatively (range 4-34 days). PIIINP and PICP also
increased post-operatively (changes not significant). By the
time of the last chemotherapy cycle (samples taken a mean of
176 days post-operatively, range 77-314 days) both PIIINP
and ICTP were marginally above, and PICP marginally
below the pretreatment level. These changes were statistically
significant only for PICP (P=0.03). The changes in the
levels of PIIINP, PICP and ICTP relative to baseline during
the therapy and the follow-up are shown in Figure 2a-c.
There was considerable interpatient variability in the changes
in the levels of the collagen metabolites after the completion
of the chemotherapy. The mean ICTP was within the
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Figure 1 Changes in PIIINP (a), PICP (b) and ICTP (c)
preceding detection of metastases. Time = 0 indicates the date of
clinical diagnosis of metastases. The metabolites are indicated as
relative values (i.e. the actual value divided by the value obtained
at time of metastases). Thus the value obtained at time of metas-
tases by definition = 1.
reference range within 5 years, and PIIINP within 8 months
after the last chemotherapy infusion. The changes in PICP
were at most a slight increase of short duration after the
completion of the post-operative chemotherapy.
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The treatment results on osteosarcoma have greatly improved
during recent decades (Link et al., 1991). There is however a
need for intensified treatment in selected patients, and thus
also for new sensitive and specific prognostic factors.
Based on our experiences on soft tissue sarcomas and
multiple myeloma as well as on prostate cancer metastatic to
bone we had reasons to expect that metabolites of type I and
III collagen could be of use in osteosarcoma (Elomaa et al.,
1992; Taube et al., 1992; Wiklund et al., 1992; Kylmala et al.,
1993).
The present study indicates that elevated concentrations of
type I and III collagen metabolites, particularly ICTP and
PIIINP, are frequent findings in untreated osteogenic sar-
coma. On the other hand, the circulating concentrations of
PICP, which as part of the type I procollagen is a charac-
teristic gene product of the osteoblastic cells, was much less
often increased, suggesting that the malignant cells are not
more active in producing this protein than are the normal
osteoblasts. AP is another product of the osteoblast, and
considered to be expressed later than type I collagen in the
phenotypic development of this cell (Stein et al., 1990). It is
interesting that this enzyme is a prognostic factor with
respect to survival in osteosarcoma, a finding that was
confirmed here, as also the prognostic implication of LD
(Link et al., 1991; Bacci et al., 1993).
We report two important findings here. Firstly, in contrast
to previous studies on these metabolites in malignant disease
our study population was made up almost exclusively of
young persons. The majority of patients had initially elevated
values of PIIINP and ICTP. It is probable that part of this
elevation is a result of the young age of the patients
(P Trivedi, unpublished data). Furthermore, the correlation
between ICTP and age suggests this.
Secondly, this study confirms our previous findings on the
effect of therapy per se on collagen metabolism (Haukipuro
et al., 1990; Wiklund et al., 1993). The intensive mul-
timodality treatment of osteosarcoma clearly affect the col-
lagen metabolism. In this study population the long disease-
free follow-up made it possible to analyse the time it takes
for collagen metabolism to normalise. For ICTP the time is
surprisingly long. However, although the pattern of decline
was similar in patients above or below 20 years (data not
shown) it should be emphasised that all patients except one
were below 35 years of age at diagnosis, and thus the type I
collagen metabolism could be expected to be more active
than in an older age. Thirdly, these findings emphasise that
clinical results from biochemical markers reflecting tissue
destruction and repair, such as the three used here, must be
interpreted with caution.
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Figure 2 The changes in PIIINP (a), PICP (b) and ICTP (c)
during the therapy and the follow-up. A, baseline value; B,
preoperative value; C, post-operative value; D, value during last
post-operative chemotherapy cycle; 1 month, values obtained 1
month after the last chemotherapy infusion, and thereafter mon-
thly up to I year after the last chemotherapy cycle (= 1 year).
From this point values are shown yearly until 10 years. Only
measurements obtained during disease-free follow-up are included
(i.e. from date of metastases all measurements are excluded).
Bottom, individual graphs for each patient. Top, mean and 95%
confidence intervals (at 7 months and 12 months after completion
of therapy less than four measurements were available, these were
excluded).
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